Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

New substituted 4-arylaminoquinazolines as potent inhibitors of breast tumor cell lines: In vitro and docking experiments

Full text
Author(s):
de Oliveira, Andre N. [1] ; Bocca, Cleverson C. [2] ; Carvalho, Joao E. [3] ; Ruiz, Ana Lucia G. [3] ; Silva, Thiago P. [2] ; Rittner, Roberto [2] ; Hoehr, Nelci F. [1]
Total Authors: 7
Affiliation:
[1] Univ Estadual Campinas, Sch Med Sci, Dept Clin Pathol, BR-13083887 Campinas, SP - Brazil
[2] Univ Estadual Campinas, Phys Organ Chem Lab, Inst Chem, BR-13083970 Campinas, SP - Brazil
[3] Univ Estadual Campinas, Pluridisciplinary Ctr Chem Biol & Agr Res, BR-13084971 Campinas, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY; v. 45, n. 9, p. 4339-4342, SEP 2010.
Web of Science Citations: 10
Abstract

The arylquinazolines represent significant advances in the clinical management of breast cancer. Nevertheless some confirmatory studies must be considered to foster the use of anti-EGFR therapies including safety and clinical use. Two 4-arylaminoquinazoline derivatives, recently synthesized, were tested as kinase inhibitors and their citotoxicities showed potent growth inhibitory activity in breast tumor cell lines (MCF-7). The predicted complex structure of quinazoline inhibitors with EGFR protein from molecular docking provided a stereoview of the binding site correlated with structure activity, affording important information about structure-based drug design. (C) 2010 Published by Elsevier Masson SAS. (AU)

FAPESP's process: 05/59649-0 - Conformational equilibria studies by nuclear magnetic resonance spectroscopy, infrared spectroscopy and theoretical calculations
Grantee:Roberto Rittner Neto
Support Opportunities: Research Projects - Thematic Grants